8-K: Elevance Health Q2 2026 Earnings Beat, Guidance Raised

Elevance Health reported strong second quarter 2026 results, exceeding expectations and leading to an increase in full-year guidance for both earnings per share and operating cash flow.

Summary

• Elevance Health announced its second quarter 2026 financial results, reporting operating revenue of $49.8 billion, a slight increase of 0.8% compared to the prior year quarter.
• Diluted EPS for the quarter was $6.71, with adjusted diluted EPS at $7.45. These results were positively impacted by favorable benefit expense performance and a significant below-the-line benefit.
• The company raised its full-year 2026 guidance, now expecting diluted EPS of at least $20.10 and adjusted diluted EPS of at least $27.00.
• Full-year operating cash flow guidance was also increased to at least $6.0 billion.
• Elevance Health plans to accelerate investments in capabilities aimed at lowering healthcare costs, improving member and provider experiences, and strengthening Carelon's integrated solutions.
• Medical membership stood at approximately 44.9 million as of June 30, 2026, a sequential decrease of 469,000 members.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with the company exceeding expectations and raising full-year guidance, despite some headwinds in membership and benefit expenses.

Positives

• Second quarter results exceeded expectations.
• Full-year 2026 adjusted diluted EPS guidance raised to at least $27.00.
• Full-year 2026 operating cash flow guidance raised to at least $6.0 billion.
• Operating revenue increased by 0.8% to $49.8 billion in Q2 2026 compared to Q2 2025.
• CarelonRx product revenue and Carelon Services risk-based solutions showed growth.
• The company repurchased 0.7 million shares for $234 million in Q2 2026.
• A quarterly dividend of $1.72 per share was declared for the third quarter of 2026.

Negatives

• Medical membership decreased by 469,000 sequentially, driven by customer transitions and anticipated attrition in Individual ACA and Medicaid.
• Benefit expense ratio increased by 80 basis points year-over-year due to expected elevated medical cost trends in government businesses.
• Operating expense ratio increased by 100 basis points, attributed to investments in workforce and capabilities.
• Health Benefits segment operating gain decreased year-over-year due to higher benefit expense and investments, despite revenue growth.
• Carelon Services operating gain decreased by 8.5% year-over-year.

Risks

• Trends in healthcare costs and utilization rates.
• Reduced enrollment in health plans.
• Ability to secure and implement sufficient premium rates.
• Impact of large-scale medical emergencies, such as public health epidemics and pandemics.
• Changes in federal, state, and international laws or regulations impacting healthcare and insurance.
• Risk of cyber-attacks or other privacy/data security incidents.
• Failure to effectively maintain and modernize information systems.
• Changes in economic and market conditions affecting liquidity and investment portfolios.

Future Outlook

Full-year 2026 guidance has been raised, with projected diluted EPS of at least $20.10 and adjusted diluted EPS of at least $27.00. Operating cash flow guidance is also increased to at least $6.0 billion. The company anticipates returning to at least 12% adjusted EPS growth in 2027.

Management Comments

• "Our second quarter results exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio."
• "We are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider connectivity, operating efficiency, and Carelons value-based solutions."
• "These actions will strengthen how we operate, improve consistency over time, and reinforce our confidence in returning to at least 12% adjusted EPS growth in 2027 off our 2026 earnings baseline."

Industry Context

StockSavvy.ai notes that Elevance Health's performance in Q2 2026, particularly its ability to raise guidance despite some membership declines and increased benefit expenses, reflects a strategic focus on cost management and integrated solutions within the competitive health insurance landscape. The acceleration of investments in capabilities like medical cost management and value-based solutions aligns with broader industry trends towards greater efficiency and member-centric care.

Comparison to Industry Standards

• Elevance Health's operating revenue growth of 0.8% in Q2 2026 is modest compared to some competitors in the managed care sector who may be experiencing higher growth rates due to market expansion or specific product successes.
• The benefit expense ratio of 89.7% is a key metric. While it increased year-over-year, it is crucial to compare this to industry benchmarks for similar health insurance providers to assess its competitiveness.
• The company's adjusted diluted EPS guidance of at least $27.00 for FY2026 needs to be benchmarked against analyst expectations and competitor guidance to determine if it represents a superior or merely in-line performance.
• The sequential decline in medical membership (469,000) is a point of concern and should be compared to membership trends of peers like UnitedHealth Group, CVS Health (Aetna), and Cigna to understand if this is an isolated issue or a broader industry challenge.

Legal Proceedings

• Potential exposure for certain historical Medicare Advantage risk adjustment data related to a CMS notice dated February 27, 2026.

Stakeholder Impact

• Shareholders: Benefit from raised full-year EPS guidance and a declared quarterly dividend.
• Employees: May be impacted by investments in workforce and capabilities.
• Providers: Potential for simplified experience and strengthened integrated solutions.
• Members: Aim for lower healthcare costs and simplified experience.

Next Steps

• Continue to accelerate targeted investments in capabilities that lower healthcare costs, simplify member and provider experience, and strengthen Carelon's integrated solutions.
• Focus on achieving at least 12% adjusted EPS growth in 2027.
• Manage expenses thoughtfully while investing in enterprise performance priorities.

Key Dates

Recommendation

While the company exceeded Q2 expectations and raised guidance, the modest revenue growth, sequential membership decline, and increased benefit expenses warrant a cautious approach. The strategic investments are positive for the long term, but the immediate pressures suggest holding the stock until these investments demonstrate more tangible positive impacts on membership and profitability.

Keywords

Elevance Health, Q2 2026 Earnings, Health Insurance, Healthcare, EPS Guidance, Operating Revenue, Carelon, Medical Membership